Clinical trials located in

Groningen

Groningen city is located in Netherlands. Currently, 20 clinical trials are being conducted in this city.

Groningen, located in the northern Netherlands, is a vibrant city known for its youthful energy, largely due to its significant student population. The city boasts the University of Groningen, established in 1614, making it one of the oldest and most prestigious universities in the Netherlands. Groningen is renowned for its rich history, visible in its well-preserved medieval architecture, including the iconic Martinitoren tower. The city is also a leader in sustainability, with extensive cycling paths and initiatives promoting green living. Its cultural scene is dynamic, with numerous museums, theaters, and music venues, reflecting its status as a creative and innovative hub.

  • CT-EU-00121228

    Study of INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma

    Conventional chondrosarcoma is a type of cancer that affects the bones. This clinical trial focuses on evaluating a new treatment for patients with unresectable (inoperable) or metastatic (spread to other parts of the body) conventional chondrosarcoma. The therapy being tested is called INBRX-109. INBRX-109 is an experimental drug, specifically a humanized antibody that targets a protein called death receptor 5 (DR5). The study aims to determine whether INBRX-109 can help patients who have this type of bone cancer.

    In this study, participants will be randomly assigned to one of two groups: one group will receive INBRX-109, and the other will receive a placebo. Neither the participants nor the researchers will know who is receiving the actual drug and who is receiving the placebo. This is known as a double-blind study. Participants will receive their assigned treatment through an intravenous infusion every three weeks. If the disease progresses, those in the placebo group will be allowed to switch to the INBRX-109 treatment.

    The primary goal of the study is to see how well INBRX-109 works in preventing the cancer from getting worse. The study will also look at overall survival rates, how long any responses to the treatment last, and the quality of life of the participants during the study. Safety and tolerability of INBRX-109 will also be evaluated by monitoring for any side effects. Participants will have regular visits and tests to check on their condition and the effects of the treatment. This clinical trial offers a potential new treatment option for patients with difficult-to-treat chondrosarcoma, aiming to improve their outcomes and quality of life.

    • INBRX-109
    • placebo
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • 24-Week Anifrolumab treatment study for primary Sjögren’s syndrome

    The ANISE-II study is a research project designed to explore the effectiveness and safety of a medication called Anifrolumab in treating Primary Sjögren’s Syndrome (pSS), a condition that affects your immune system. This study is particularly important because it aims to find new ways to manage pSS, which can cause symptoms like dry mouth and eyes, fatigue, and joint pain.

    In this study, participants will be divided into two groups. One group will receive Anifrolumab, a medication given through an IV (intravenous infusion) once every four weeks for a total of 24 weeks. The other group will receive a placebo, which is a treatment that looks like the medication but does not contain any active substance. This is done to compare the effects of Anifrolumab with no treatment at all.

    The main goal of the ANISE-II study is to see if Anifrolumab can help improve symptoms and quality of life for people with pSS. This will be measured using something called the Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS) at week 24, which looks at various aspects of the disease, including systemic disease activity, patient-reported symptoms, and the health of tear and salivary glands.

    To be eligible for this study, patients must meet certain criteria, such as having been diagnosed with pSS according to specific guidelines, having had the disease for no more than 10 years. They must also experience a certain level of disease activity and symptoms.

    • placebo
    • Anifrolumab
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • ARTEMIS study: Protecting kidney health in heart surgery patients with Ravulizumab

    The ARTEMIS study aims to find a new way to protect people with chronic kidney disease (CKD) undergoing heart surgery requiring the use of a heart-lung machine, also known as cardiopulmonary bypass (CPB). The main aim of this study is to see if a single dose of a drug called ravulizumab given intravenously can reduce the risk of serious kidney problems after surgery, compared with a placebo. Kidney issues are grouped under serious adverse events, and investigators will monitor them for up to 90 days after surgery. The study is carefully controlled and participants will not know whether they are receiving ravulizumab or a placebo to ensure the results are unbiased. This is an important test for people with chronic kidney disease undergoing heart surgery because it may lead to better outcomes and a lower risk of kidney damage after surgery.

    • placebo
    • Ravulizumab
  • Safety study of new treatment in locally advanced or metastatic solid tumors

    This study is focused on researching a new treatment called RO7502175 for various serious types of cancer, including lung cancer, stomach cancer, cervical cancer, and more. The primary objectives of the study are to assess the safety of RO7502175, study its movement within the body (pharmacokinetics), and evaluate its potential to slow down or halt these types of cancer. Additionally, the researchers aim to investigate the effectiveness of this new treatment when used alone and in combination with another drug called atezolizumab. The study is divided into two parts. In the first part, the researchers will initiate with a smaller dose of the drug and gradually increase it to determine the optimal dosage. Once the appropriate dose is established, the second part of the study will involve treating a larger group of participants with this determined dosage.

    • RO7502175- new potential medication for solid tumors
    • Atezolizumab
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    • Volrustomig
    • Pemetrexed
    • Carboplatin
    • Pembrolizumab
    • Paclitaxel
  • Testing new immunotherapy combinations for non-small-cell lung cancer

    This study is testing a new treatment for non-small cell lung cancer that has not yet been treated with drugs. In the study, researchers will look at the effects of combining different immunotherapy drugs and their safety and effectiveness in treating cancer. Participants will receive various combinations of the drugs pembrolizumab, dostarlimab, belrestotug and GSK6097608. The study will last several years and will monitor the effects of different drug combinations and any potential side effects. The study aims to find new ways to treat lung cancer with fewer negative side effects.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Trial for high-risk Lymphoma Patients comparing Axicabtagene Ciloleucel and standard therapy

    In this study, the researchers are trying to find out if a new drug called Axicabtagene Ciloleucel is a better first treatment for a type of blood cancer known as high-risk large B-cell lymphoma, compared to the current standard treatment. This is a big study, done in many places, where patients will be randomly picked to get either the new drug or the current standard treatment. Five years after the last patient joins the study, those who had the new drug will join another study to see how they are doing for the next 10 years. The study will look at a few things, like how long until the disease gets worse, how many people’s cancer has gone away after the treatment, and how their quality of life and health status are, using different questionnaires.

    • Axicabtagene Ciloleucel
    • Prednisone
    • Fludarabine
    • Vincristine
    • Doxorubicin
    • Etoposide
    • Cyclophosphamide
    • Rituximab
  • Study on new immunotherapy combinations for untreated advanced lung cancer

    This is a study of patients whose non-small cell lung cancer is at an advanced stage (cannot be cured by surgery or has spread to other parts of the body) and has not been previously treated. The study will test new combinations of immunotherapy (drugs that support the immune system in the fight against cancer) and compare them with a single immunotherapy drug. Scientists want to find out how well these combinations work and how safe they are. The study will also look at how the body processes these drugs. The drugs used in this study are called Belrestoug, GSK4428859A and EOS884448, but these names all refer to the same drug. Scientists will measure the effectiveness of the drugs by looking at how many patients have their cancer shrink and how long it takes for the cancer to start growing again or before the patient dies. They will also record any side effects that may occur during the study and for 90 days after the last treatment dose.

    • Belrestotug
    • Dostarlimab
    • GSK6097608- new potential medication for solid tumors
    • Pembrolizumab
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    • Cilta-cel
    • Fludarabine
    • Lenalidomide
    • Dexamethasone
    • Cyclophosphamide
    • Bortezomib
  • Understanding trastuzumab deruxtecan treatment for advanced lung cancer

    This study is testing a new lung cancer treatment, Trastuzumab Deruxtecan, to see if it’s effective and safe for patients with a certain type of advanced lung cancer (Non-Small Cell Lung Cancer with HER2 mutations). Patients in the study either receive this new treatment or standard care (cisplatin or carboplatin + pembrolizumab + pemetrexed). The main goal is to see if the new treatment helps patients live longer without their cancer getting worse and to monitor any side effects.

    • Trastuzumab deruxtecan
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
  • Children’s study on sotatercept for pulmonary arterial hypertension

    This study evaluates the safety and tolerability of sotatercept in children aged 1 to 17 years with Pulmonary Arterial Hypertension (PAH). Over 24 weeks, 42 participants will receive sotatercept to understand how the body processes the drug and its effects. The study will monitor various health parameters, including blood pressure, heart function, and quality of life. Key outcomes include measuring serum concentrations of sotatercept, changes in heart and lung function, and overall well-being. This trial aims to improve treatment for children with PAH.

    • Sotatercept
  • Evaluation of Bemarituzumab in patients with solid tumors overexpressing the FGFR2b receptor

    The study concerns patients with solid tumors that are characterized by excessive expression of the FGFR2b receptor (Fibroblast Growth Factor Receptor 2b). In particular, this includes cancers such as head and neck squamous cell carcinoma, triple negative breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, epithelial ovarian cancer, endometrial adenocarcinoma and cervical cancer. The therapy that will be used in this study is bemarituzumab (also known as AMG 552), administered by intravenous infusion.

    The aim of the study is to assess the safety and tolerability of bemarituzumab and its preliminary anticancer effectiveness. Patients with the above cancers whose disease recurs or does not respond to standard therapies may be eligible to participate in the study.

    Patients must have confirmed recurrent or refractory cancer that is not suitable for surgical treatment. An additional condition is excessive expression of the FGFR2b receptor in their tumor. The experimental therapy includes two phases: in the first phase, determining the optimal dose, and in the second, expanding the therapy to a larger group of patients using a previously determined dose.

    • Bemarituzumab
  • Exploring a new treatment for bipolar II disorder

    This study is testing a drug called GH001 (Mebufotenin) in people who suffer from bipolar II disorder and are currently going through a phase of major depression. Bipolar II disorder is a disease that causes mood swings. At the moment we are focusing on people who are in a depressed mood. The drug will be tested in various health centers and it will only apply to one group of people, there will be no comparisons with other groups. The study will involve approximately 15 people diagnosed with this disease by doctors. Patients will receive one, two or three doses of GH001 daily, depending on what is best for them. Then, the severity of their depression will be checked using a tool called MADRS, which gives points from 0 to 60; the more points, the more serious the depression.

    • Mebufotenin/GH001
  • Examining povorcitinib for treating hidradenitis suppurativa

    This study is about a drug called Povorcitinib, also known as INCB054707. It’s being tested on people who have moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. The trial will last for 12 weeks, and then there will be an extension period of 42 weeks. The aim of the trial is to see whether the drug is both safe, and effective enough to reduce the symptoms by at least 50%, without increasing certain symptoms like abscesses or tunnels formed by the disease. The study will also look at whether the drug significantly reduces skin pain and improves quality of life.

    • povorcitinib
  • Studying rilvegostomig in the treatment of advanced or metastatic lung cancer

    This clinical trial evaluates rilvegostomig, a new drug for advanced non-small cell lung cancer (NSCLC). The study involves people with stage III or IV NSCLC and explores if rilvegostomig is safe and effective. It’s conducted in several parts, including dose escalation and expansion, to determine the best dose and its impact on the cancer. The trial measures how patients respond to the treatment and monitors for any side effects.

    • Rilvegostomig

See more clinical trials in other cities in Netherlands:

.